JAK2 and type 1 diabetes mellitus: A case report showed that JAK1/JAK2 inhibitor ruxolitinib normalized blood-glucose levels and discontinued exogenous insulin in a patient with type 1 diabetes caused by STAT1 gain-of-function (52).